Suzetrigine: an analgesic of the future? – a clinical review
Abstract
Suzetrigine is one of the revolutionary non-opioid analgesics developed with the specific intention of managing acute pain, mild to severe in intensity.As a blocker of voltage-gated sodium channels (Nav), which specifically target Nav1.7,Nav1.8, and Nav1.9, it effectively modulates the signalling pathways for pain while avoiding most of the adverse effects associated with the central nervous and the gastrointestinal systems seen in conventional analgesics and opioids.Suetrigine has a highly optimized pharmacological profile and provides advantages over existing pain management therapies, which often have risks of dependence, addiction, and adverse effects such as sedation and respiratory complications.In clinical trials involving more than 2,447 participants, suzetrigine proved to be safe and effective in reducing the intensity of pain without any risk of abuse or respiratory depression.The approval of suzetrigine by the U.S. Food and Drug Administration is a significant development in pain management strategies.By addressing the shortcomings of current analgesics, including NSAIDs, acetaminophen, and opioids, suzetrigine offers a much-needed alternative for patients suffering from acute pain conditions.In addition, its novel mechanism of action avoids the gastrointestinal and renal risks of NSAIDs but has the potential for long-
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.